Formulations of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
Pharmaceutical compositions and single unit dosage forms of (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as cancer, an inflammatory disease and/or an immune-related disorder.
1. An oral dosage form in the form of a capsule which comprises: 1) Compound A of the following structure:
or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, clathrate, stereoisomer, tautomer, or racemic mixtures thereof, at an amount of about 0.1 to about 3 weight percent of the total weight of the dosage form; 2) a carrier or excipient at an amount of about 90 to 99.9 weight percent of total weight of the oral dosage form, wherein the carrier or excipient is a mixture of starch and lactose; and 3) a lubricant at an amount of 0.01 to 1 weight percent of total weight of the oral dosage form, wherein the lubricant is stearic acid.
2. The oral dosage form of claim 1 , wherein Compound A is present at an amount of about 0.1 to about 1 weight percent of total weight of the dosage form.
3. The oral dosage form of claim 1 , wherein the carrier or excipient is present at an amount of about 95 to about 99.9 weight percent of total weight of the dosage form.
4. The oral dosage form of claim 1 , wherein the starch is pregelatinized starch.
5. The oral dosage form of claim 1 , wherein the lactose is anhydrous lactose.
6. The oral dosage form of claim 1 , wherein the lubricant is presented at an amount of 0.1 to 1 weight percent of total weight of the oral dosage form.
7. The oral dosage form of claim 6 , wherein the lubricant is present at an amount of 0.1 to 0.5 weight percent of total weight of the dosage form.
8. An oral dosage form which weighs about 75 mg and comprises: 1) Compound A of the following structure:
or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, clathrate, stereoisomer, tautomer, or racemic mixtures thereof, at an amount that provides 0.3 mg potency of Compound A; 2) a pharmaceutically acceptable carrier or excipient, wherein the carrier or excipient is a mixture of starch and lactose; and 3) a lubricant, wherein the lubricant is stearic acid.
9. The dosage form of claim 8 , wherein the starch is pregelatinized starch.
10. The dosage form of claim 9 , wherein the pregelatinized starch is present at an amount of about 18.075 mg.
11. The dosage form of claim 8 , wherein the stearic acid is present at an amount of about 0.225 mg.
12. The dosage form of claim 8 , wherein the lactose is anhydrous lactose.
13. The dosage form of claim 12 , wherein the anhydrous lactose is present at an amount that brings the total weight of the composition to about 75 mg.
14. The dosage form of claim 8 , which is to be administered in the form of a standard size 4 or larger capsule.
15. An oral dosage form which weighs about 75 mg and comprises: 1) Compound A of the following structure:
or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, clathrate, stereoisomer, tautomer, or racemic mixtures thereof, at an amount that provides 0.1 mg potency of Compound A; 2) a pharmaceutically acceptable carrier or excipient, wherein the carrier or excipient is a mixture of starch and lactose; and 3) a lubricant, wherein the lubricant is stearic acid.
16. The dosage form of claim 15 , wherein the starch is pregelatinized starch.
17. The dosage form of claim 16 , wherein the pregelatinized starch is present at an amount of about 18.75 mg.
18. The dosage form of claim 15 , wherein the stearic acid is present at an amount of about 0.225 mg.
19. The dosage form of claim 15 , wherein the lactose is anhydrous lactose.
20. The dosage form of claim 19 , wherein the anhydrous lactose is present at an amount that brings the total weight of the composition to about 75 mg.
21. The dosage form of claim 15 , which is to be administered in the form of a standard size 4 or larger capsule.
22. An oral dosage form which weighs about 150 mg and comprises: 1) Compound A of the following structure:
or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, clathrate, stereoisomer, tautomer, or racemic mixtures thereof, at an amount that provides 0.2 mg potency of Compound A; 2) a pharmaceutically acceptable carrier or excipient, wherein the carrier or excipient is a mixture of starch and lactose; and 3) a lubricant, wherein the lubricant is stearic acid.
23. The dosage form of claim 22 , wherein the starch is pregelatinized starch.
24. The dosage form of claim 23 , wherein the pregelatinized starch is present at an amount of about 37.5 mg.
25. The dosage form of claim 22 , wherein the stearic acid is present at an amount of about 0.45 mg.
26. The dosage form of claim 22 , wherein the lactose is anhydrous lactose.
27. The dosage form of claim 26 , wherein the anhydrous lactose is present at an amount that brings the total weight of the composition to about 150 mg.
28. The dosage form of claim 22 , which is to be administered in the form of a standard size 3 or larger capsule.
29. An oral dosage form which weighs about 125 mg and comprises: 1) Compound A of the following structure:
or a pharmaceutically acceptable prodrug, salt, solvate, hydrate, clathrate, stereoisomer, tautomer, or racemic mixtures thereof, at an amount that provides 0.5 mg potency of Compound A; 2) a pharmaceutically acceptable carrier or excipient, wherein the carrier or excipient is a mixture of starch and lactose; and 3) a lubricant, wherein the lubricant is stearic acid.
30. The dosage form of claim 29 , wherein the starch is pregelatinized starch.
31. The dosage form of claim 30 , wherein the pregelatinized starch is present at an amount of about 31.25 mg.
32. The dosage form of claim 29 , wherein the stearic acid is present at an amount of about 0.375 mg.
33. The dosage form of claim 29 , wherein the lactose is anhydrous lactose.
34. The dosage form of claim 33 , wherein the anhydrous lactose is present at an amount that brings the total weight of the composition to about 125 mg.
35. The dosage form of claim 29 , which is to be administered in the form of a standard size 3 or larger capsule.